Response rate of fibrosarcoma cells to cytotoxic drugs on the expression level correlates to the therapeutic response rate of fibrosarcomas and is mediated by regulation of apoptotic pathways
Authors:
- Marcus LehnhardtMLMarcus Lehnhardt
- Ludger Klein-HitpassLKLudger Klein-Hitpass
- Cornelius KuhnenCKCornelius Kuhnen
- Heinz Herbert HomannHHHeinz Herbert Homann
- Adrien DaigelerADAdrien Daigeler
- Hans Ulrich SteinauHSHans Ulrich Steinau
- Sonja RoehrsSRSonja Roehrs
- Laura SchnoorLSLaura Schnoor
- Lars SteinstraesserLSLars Steinstraesser
- Oliver MuellerOMOliver Mueller
Open Access
- 7 July 2005
- journal article
- Published by Springer Nature in BMC Cancer
- Vol. 5 (1) , 74
Abstract
Background: Because of the high resistance rate of fibrosarcomas against cytotoxic agents clinical chemotherapy of these tumors is not established. A better understanding of the diverse modes of tumor cell death following cytotoxic therapies will provide a molecular basis for new chemotherapeutic strategies. In this study we elucidated the response of a fibrosarcoma cell line to clinically used cytostatic agents on the level of gene expression. Methods: HT1080 fibrosarcoma cells were exposed to the chemotherapeutic agents doxorubicin, actinomycin D or vincristine. Total RNA was isolated and the gene expression patterns were analyzed by microarray analysis. Expression levels for 46 selected candidate genes were validated by quantitative real-time PCR. Results: The analysis of the microarray data resulted in 3.309 (actinomycin D), 1.019 (doxorubicin) and 134 (vincristine) probesets that showed significant expression changes. For the RNA synthesis blocker actinomycin D, 99.4% of all differentially expressed probesets were under-represented. In comparison, probesets down-regulated by doxorubicin comprised only 37.4% of all genes effected by this agent. Closer analysis of the differentially regulated genes revealed that doxorubicin induced cell death of HT1080 fibrosarcoma cells mainly by regulating the abundance of factors mediating the mitochondrial (intrinsic) apoptosis pathway. Furthermore doxorubicin influences other pathways and crosstalk to other pathways (including to the death receptor pathway) at multiple levels. We found increased levels of cytochrome c, APAF-1 and members of the STAT-family (STAT1, STAT3), while Bcl-2 expression was decreased. Caspase-1, -3, -6, -8, and -9 were increased indicating that these proteases are key factors in the execution of doxorubicin mediated apoptosis. Conclusion: This study demonstrates that chemotherapy regulates the expression of apoptosis-related factors in fibrosarcoma cells. The number and the specific pattern of the genes depend on the used cytotoxic drug. The response rates on the gene expression level, i.e. the number of genes regulated by the drugs actinomycin D, doxorubicin and vincristine, correlate to the clinical effectiveness of the drugs. Doxorubicin seems to exert its cytotoxic mechanism by regulating genes, which are involved in several different apoptosis regulating pathways. The exact knowledge of the genes affected by the drugs will help to understand the diverse modes of soft tissue sarcoma cell death in response to cytotoxic therapies.Keywords
This publication has 90 references indexed in Scilit:
- LyGDI functions in cancer metastasis by anchoring Rho proteins to the cell membraneMolecular Carcinogenesis, 2004
- RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cellsThe Prostate, 2004
- Chemotherapy-induced Apoptosis of S-type Neuroblastoma Cells Requires Caspase-9 and Is Augmented by CD95/Fas StimulationJournal of Biological Chemistry, 2004
- Apoptosome-independent Pathway for ApoptosisJournal of Biological Chemistry, 2003
- Caspase inhibition switches doxorubicin-induced apoptosis to senescenceOncogene, 2003
- Cell death regulation by the Bcl‐2 protein family in the mitochondriaJournal of Cellular Physiology, 2003
- Molecular characterisation of soft tissue tumours: a gene expression studyThe Lancet, 2002
- The EORTC Soft Tissue and Bone Sarcoma GroupEuropean Journal of Cancer, 2002
- Crosstalk between the interleukin-6 (IL-6)-JAK-STAT and the glucocorticoid-nuclear receptor pathway: synergistic activation of IL-6 response element by IL-6 and glucocorticoidJournal of Endocrinology, 1998
- Anthracycline ResistanceActa Oncologica, 1989